A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer

S
Shadia Jalal, MD

Primary Investigator

Overview

The purpose of this study is to find out if the combination of guadecitabine with carboplatin is better or worse than the usual approach for small cell lung cancer.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Small Cell Lung Cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patient should not have received more than 1 prior line of chemotherapy (could have received immunotherapy which does not count as chemotherapy).
  • Male and female subjects of child- bearing potential must agree to use a double-barrier method of birth control from the screening visit through 3 months after the last dose of study drug.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 20 Nov 2022. Study ID: 1902370856 (LUN17-302)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center